Qualigen Therapeutics Inc (NASDAQ:QLGN) — Market Cap & Net Worth
Market Cap & Net Worth: Qualigen Therapeutics Inc (QLGN)
Qualigen Therapeutics Inc (NASDAQ:QLGN) has a market capitalization of $4.74 Million ($4.74 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28472 globally and #5604 in its home market, demonstrating a -8.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qualigen Therapeutics Inc's stock price $2.33 by its total outstanding shares 2033072 (2.03 Million). Analyse QLGN cash flow metrics to see how efficiently the company converts income to cash.
Qualigen Therapeutics Inc Market Cap History: 2015 to 2026
Qualigen Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $432.03 Billion to $4.74 Million (-68.29% CAGR).
Index Memberships
Qualigen Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #841 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2696 of 3165 |
Weight: Qualigen Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Qualigen Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qualigen Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.74x
Qualigen Therapeutics Inc's market cap is 10.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $83.71 Billion | $9.78 Million | -$7.86 Million | 8563.30x | N/A |
| 2018 | $15.25 Billion | $5.80 Million | -$16.87 Million | 2627.59x | N/A |
| 2019 | $4.29 Billion | $5.56 Million | -$1.79 Million | 772.28x | N/A |
| 2020 | $3.06 Billion | $4.31 Million | -$20.42 Million | 710.53x | N/A |
| 2021 | $1.09 Billion | $5.65 Million | -$17.90 Million | 192.39x | N/A |
| 2022 | $131.03 Million | $4.98 Million | -$21.03 Million | 26.29x | N/A |
| 2023 | $55.91 Million | $5.20 Million | -$13.42 Million | 10.74x | N/A |
Competitor Companies of QLGN by Market Capitalization
Companies near Qualigen Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Qualigen Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Qualigen Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Qualigen Therapeutics Inc's market cap moved from $432.03 Billion to $ 4.74 Million, with a yearly change of -68.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.74 Million | +2.64% |
| 2025 | $4.62 Million | -46.08% |
| 2024 | $8.56 Million | -84.69% |
| 2023 | $55.91 Million | -57.33% |
| 2022 | $131.03 Million | -87.95% |
| 2021 | $1.09 Billion | -64.45% |
| 2020 | $3.06 Billion | -28.72% |
| 2019 | $4.29 Billion | -71.85% |
| 2018 | $15.25 Billion | -81.79% |
| 2017 | $83.71 Billion | -87.85% |
| 2016 | $688.70 Billion | +59.41% |
| 2015 | $432.03 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Qualigen Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.74 Million USD |
| MoneyControl | $4.74 Million USD |
| MarketWatch | $4.74 Million USD |
| marketcap.company | $4.74 Million USD |
| Reuters | $4.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS tha… Read more